Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

c-Raf in KRas Mutant Cancers: A Moving Target.

Cancer cell - 12 Feb 2018

McCormick Frank

Abstract excerpt

Therapies for KRas cancers remain a major clinical need. In the current issue of Cancer Cell, Sanclemente and coworkers in Mariano Barbacid's group validate c-Raf as a prime target for these cancers. c-Raf ablation caused regression of advanced KRasG12V/Trp53 tumors, without obvious systemic toxicity and without affecting MAPK signaling.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Proto-Oncogene Proteins
Share to Cell Line, Tumor
Share to Genes, ras

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 29438690
DOI: 10.1016/j.ccell.2018.01.017
PMCID: PMC6464632

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

c-Raf in KRas Mutant Cancers: A Moving Target.PMID 29438690Read ↗

c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.Semantic proximity Read ↗

Targeting KRAS mutant lung cancer: light at the end of the tunnel.Semantic proximity Read ↗

Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.Semantic proximity Read ↗

Improving Prospects for Targeting RAS.Semantic proximity Read ↗

Targeting the MAPK Pathway in RAS Mutant Cancers.Semantic proximity Read ↗

Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.Semantic proximity Read ↗

RAS-ing the bar in the treatment of KRAS-mutant cholangiocarcinoma.Semantic proximity Read ↗

Targeting the MAPK Pathway in KRAS-Driven Tumors.Semantic proximity Read ↗

RAS at 40: Update from the RAS Initiative.Semantic proximity Read ↗

Targeting Mutant KRAS for Immunogenic Cell Death Induction.Semantic proximity Read ↗

Raf: a strategic target for therapeutic development against cancer.Semantic proximity Read ↗

Targeting RAS-mutant cancer cells using a synthetic RAS-activated cancer killing system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.